Thor Medical ASA (TRMED) - Total Liabilities
Based on the latest financial reports, Thor Medical ASA (TRMED) has total liabilities worth Nkr87.50 Million NOK (≈ $9.21 Million USD) as of June 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore net asset growth rate of Thor Medical ASA to track the company's year-over-year net asset growth rate.
Thor Medical ASA - Total Liabilities Trend (2019–2024)
This chart illustrates how Thor Medical ASA's total liabilities have evolved over time, based on quarterly financial data.
Thor Medical ASA Competitors by Total Liabilities
The table below lists competitors of Thor Medical ASA ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Ample Electronic Technology Co Ltd
TWO:4760
|
Taiwan | NT$700.34 Million |
|
CARGO Therapeutics, Inc. Common Stock
NASDAQ:CRGX
|
USA | $20.91 Million |
|
Immersion Corporation
NASDAQ:IMMR
|
USA | $870.72 Million |
|
Kore Potash Plc
AU:KP2
|
Australia | AU$453.96K |
|
GOCL Corporation Limited
NSE:GOCLCORP
|
India | Rs7.54 Billion |
|
Ontex Group NV
BR:ONTEX
|
Belgium | €1.21 Billion |
|
Rhom Bho Property Public Company Limited
BK:TITLE
|
Thailand | ฿12.09 Billion |
|
Ascom Holding AG
SW:ASCN
|
Switzerland | CHF119.70 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Thor Medical ASA's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see how much is Thor Medical ASA worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 8.87 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.18 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Thor Medical ASA's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Thor Medical ASA (2019–2024)
The table below shows the annual total liabilities of Thor Medical ASA from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | Nkr77.30 Million ≈ $8.13 Million |
+31.22% |
| 2023-12-31 | Nkr58.91 Million ≈ $6.20 Million |
+28.62% |
| 2022-12-31 | Nkr45.80 Million ≈ $4.82 Million |
-70.67% |
| 2021-12-31 | Nkr156.16 Million ≈ $16.43 Million |
+14.87% |
| 2020-12-31 | Nkr135.94 Million ≈ $14.31 Million |
+2874.01% |
| 2019-12-31 | Nkr4.57 Million ≈ $481.00K |
-- |
About Thor Medical ASA
Thor Medical ASA produces and supplies alpha-particle emitters for cancer therapy in Norway. It develops Ra224, an isotope of radium; Pb-212, a radioactive isotope of lead; and Th-228, a radioactive isotope of thorium. The company was incorporated in 2009 and is headquartered in Oslo, Norway.